|
Astellas Finds Relief in FDA Approval of Overactive Bladder Drug After Dicey Ad Comm Meeting
Astellas nabbed a much-needed approval last week as its overactive bladder drug Myrbetriq received an FDA go-ahead despite a shaky advisory committee meeting in April.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives